These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 37289635)

  • 61. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
    Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
    Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Poor Ovarian Response to Stimulation for In Vitro Fertilization].
    Spremović-Radjenović S; Bila J; Gudović A; Vidaković S; Dokić M; Radunović N
    Srp Arh Celok Lek; 2015; 143(5-6):354-61. PubMed ID: 26259413
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Stop GnRH-Agonist Combined With Multiple-Dose GnRH-Antagonist Protocol for Patients With "Genuine" Poor Response Undergoing Controlled Ovarian Hyperstimulation for IVF.
    Orvieto R; Kirshenbaum M; Galiano V; Elkan-Miller T; Zilberberg E; Haas J; Nahum R
    Front Endocrinol (Lausanne); 2020; 11():182. PubMed ID: 32528403
    [No Abstract]   [Full Text] [Related]  

  • 64. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
    Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G
    Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
    Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Gonadotropin-releasing hormone antagonist protocol in patients with risk of poor response to ovarian stimulation in IVF-ET].
    Sun Y; Zhu YM
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 May; 38(3):305-10. PubMed ID: 19504641
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders.
    DiLuigi AJ; Engmann L; Schmidt DW; Benadiva CA; Nulsen JC
    Fertil Steril; 2011 Jun; 95(8):2531-3. PubMed ID: 21324455
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial.
    Gizzo S; Andrisani A; Esposito F; Noventa M; Di Gangi S; Angioni S; Litta P; Gangemi M; Nardelli GB
    Gynecol Endocrinol; 2014; 30(12):902-8. PubMed ID: 25268567
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative prospective study of 2 ovarian stimulation protocols in poor responders: effect on implantation rate and ongoing pregnancy.
    Merviel P; Cabry-Goubet R; Lourdel E; Devaux A; Belhadri-Mansouri N; Copin H; Benkhalifa M
    Reprod Health; 2015 May; 12():52. PubMed ID: 26025412
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Use of microdose GnRH agonist protocol in women with low ovarian volumes undergoing IVF.
    Sharara FI; McClamrock HD
    Hum Reprod; 2001 Mar; 16(3):500-3. PubMed ID: 11228219
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix.
    Tavaniotou A; Albano C; Smitz J; Devroey P
    Hum Reprod; 2001 Apr; 16(4):663-7. PubMed ID: 11278214
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
    König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
    Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A comparative study of luteal estradiol pre-treatment in GnRH antagonist protocols and in micro dose flare protocols for poor-responding patients.
    Davar R; Rahsepar M; Rahmani E
    Arch Gynecol Obstet; 2013 Jan; 287(1):149-53. PubMed ID: 22923150
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Flexible Antagonist versus Agonist Flare Protocol in Women above 40 Undergoing IVF, A retrospective Cohort Study.
    Hassabelnabi EAF; Badreldin MA; Behery MA; Rageh KA; Ali EA
    JBRA Assist Reprod; 2023 Sep; 27(3):381-385. PubMed ID: 37134016
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Luteal phase characteristics following GnRH antagonist or agonist treatment - a comparative study.
    Friedler S; Gilboa S; Schachter M; Raziel A; Strassburger D; Ron El R
    Reprod Biomed Online; 2006 Jan; 12(1):27-32. PubMed ID: 16454930
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Individualized FSH dosing based on ovarian reserve testing in women starting IVF/ICSI: a multicentre trial and cost-effectiveness analysis.
    van Tilborg TC; Oudshoorn SC; Eijkemans MJC; Mochtar MH; van Golde RJT; Hoek A; Kuchenbecker WKH; Fleischer K; de Bruin JP; Groen H; van Wely M; Lambalk CB; Laven JSE; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2485-2495. PubMed ID: 29121350
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Luteal-phase ovarian stimulation increases the number of mature oocytes in older women with severe diminished ovarian reserve.
    Rashtian J; Zhang J
    Syst Biol Reprod Med; 2018 Jun; 64(3):216-219. PubMed ID: 29564925
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Dual trigger with the combination of gonadotropin-releasing hormone agonist and standard dose of human chorionic gonadotropin improves
    Mutlu I; Demirdag E; Cevher F; Erdem A; Erdem M
    J Obstet Gynaecol; 2022 Jul; 42(5):1239-1244. PubMed ID: 34565274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.